Department of Pathology and Laboratory Medicine, Children's Hospital Los Angeles, 4650 Sunset Blvd, MS#32, Los Angeles, CA 90027, USA; Department of Pathology, Keck School of Medicine of the University of Southern California, Los Angeles, CA, USA.
Clinical Microbiology Service, Department of Pathology and Laboratory Medicine, Memorial Sloan Kettering Cancer Center, 327 East 64th Street, CLM-522, NY 10065, USA; Infectious Disease Service, Department of Medicine, Memorial Sloan Kettering Cancer Center, New York, NY, USA.
Clin Lab Med. 2022 Jun;42(2):147-160. doi: 10.1016/j.cll.2022.02.007. Epub 2022 Mar 8.
SARS-CoV-2 was identified and diagnostic methods developed at an impressive speed due in great part to the wider use of molecular methods in 2019 compared with 2002 during the SARS pandemic. The development of rapid and novel molecular diagnostic assays, leveraging of the high adaptability of molecular tests, and the integration of SARS-CoV-2 genotyping into public health, clinical, and research laboratories have been some of the successes in SARS-CoV-2 molecular testing. The main challenges are related to regulatory hurdles, supply chain constraints, and laboratory preparation.
由于 2019 年与 2002 年 SARS 流行期间相比，分子方法的广泛应用，SARS-CoV-2 得以迅速被发现，诊断方法也得以快速开发。快速新颖的分子诊断检测方法的发展、分子检测的高适应性的利用以及 SARS-CoV-2 基因分型整合到公共卫生、临床和研究实验室中，是 SARS-CoV-2 分子检测的一些成功案例。主要挑战与监管障碍、供应链限制和实验室准备有关。
